Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).
Lisa A. Carey
Consultant or Advisory Role - GlaxoSmithKline (U); Roche/Genentech (U)
Research Funding - GlaxoSmithKline; Roche/Genentech
William Thomas Barry
No relevant relationships to disclose
Brandy Pitcher
No relevant relationships to disclose
Katherine A. Hoadley
No relevant relationships to disclose
Maggie Chon U. Cheang
Employment or Leadership Position - Pam50 assay
Carey K. Anders
Consultant or Advisory Role - Roche/Genentech (U)
N. Lynn Henry
No relevant relationships to disclose
Sara M. Tolaney
Consultant or Advisory Role - Genentech (U)
Research Funding - Roche/Genentech
Chau T. Dang
Research Funding - GlaxoSmithKline; Roche/Genentech
Ian E. Krop
Consultant or Advisory Role - Roche/Genentech (U)
Research Funding - Roche/Genentech
Lyndsay Harris
No relevant relationships to disclose
Donald A. Berry
No relevant relationships to disclose
Charles M. Perou
Employment or Leadership Position - Bioclassifier; University Genomics
Eric P. Winer
Consultant or Advisory Role - Roche/Genentech (U)
Research Funding - GlaxoSmithKline; Roche/Genentech
Clifford A. Hudis
No relevant relationships to disclose